Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens

June 1, 2026 4:43 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $140.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found